ライフサイエンスコーパス: tumor staging

1 ive imaging of sentinel lymph nodes in solid tumor staging.

2 in molecular characteristics with pathologic tumor staging.

3 hen combined with serum alpha fetoprotein or tumor staging.

4 essed clinical relevance based on changes in tumor staging.

5 the accuracy of CT, MR, and scintigraphy for tumor staging.

6 Both CT and MR perform poorly for local tumor staging.

7 TE PET/CT were follow-up (24.4%) and initial tumor staging (23.4%).

8 nts underwent laparoscopy after conventional tumor staging; 89 were also staged with laparoscopic ult

9 Tumor staging according to the American Joint Committee

10 copic ultrasonography was superior to CT for tumor staging accuracy (67% vs. 41%; P < 0.001) but equi

11 Interobserver agreement was excellent for tumor staging (American Joint Committee on Cancer/Union

12 ogist is critical for patient management for tumor staging and assessing treatment response.

13 menopausal status, comorbidity estimate) and tumor staging and characteristics (tumor size, number of

14 he significant association of synuclein with tumor staging and clinical outcome (P = .002).

15 t imaging to provide detailed information on tumor staging and grading, evaluating treatment, and det

16 data indicate that locoregional LND improves tumor staging and leads to a favorable oncologic outcome

17 ancer cells circulating in blood may improve tumor staging and patient selection for targeted therapy

18 lating cell-free DNA (cfDNA) correlates with tumor staging and prognosis.

19 ost-LT surveillance, provide a framework for tumor staging and risk stratification, and select candid

20 calculated any differences in diagnosis and tumor staging and the potential impact of differences in

21 The examinations were performed in terms of tumor staging and, in some instances, also of primary tu

22 Overall survival correlated with tumor staging, and 92% of patients were diagnosed with a

23 iation therapy, and surgery), refinements in tumor staging, and better supportive care have significa

24 n, their distinctive patterns in relation to tumor staging, and their recurrence across different tum

25 Treatment strategies should be affected by tumor staging at presentation.

26 uveal melanoma and adequate records to allow tumor staging by American Joint Committee on Cancer (AJC

27 to April 1, 2011, adequate records to allow tumor staging by the AJCC criteria, and follow-up for me

28 and a prognostic score-integrating ITA.LI.CA tumor staging, CPS, ECOG performance status, and AFP.

29 data, demographics, histologic diagnoses and tumor staging data were collected.

30 mages from 78 patients who were referred for tumor staging for the presence of vascular (18)F-FDG upt

31 hogenesis of HCC may provide new markers for tumor staging, for assessment of the relative risk of tu

32 Based on tumor staging (I, II, III, and IV), features that showed

33 Specific indications may include tumor staging, identifying patients who would benefit fr

34 e current literature on (18)F-FDG PET/CT for tumor staging in children, summarizing questions that ha

35 atures that showed significant increase with tumor staging included age at presentation (57, 58, 60,

36 ole, as it allows the pathologist to provide tumor-staging information necessary for an appropriate c

37 Present tumor staging is mainly based on local tumor extension,

38 As we develop new approaches for tumor staging, it is important to understand current ben

39 pression in human colon cancer in respect to tumor staging, NOS-expressing cell type(s), nitrotyrosin

40 Pathologic tumor staging of the explanted liver was based on the Am

41 Tumor staging on the basis of the PET/CT and MR/PET stud

42 es of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognos

43 Commonly used for tumor staging, PET/CT aided in the detection of the prim

44 The overall change in tumor staging rate was 24% (97 of 405 patients; 95% CI,

45 with better patient survival independent of tumor staging, site location, microsatellite instability

46 ITA.LI.CA prognostic system includes both a tumor staging-stratifying patients with HCC into six mai

47 udy have prompted the development of a novel tumor staging system based on TVI.

48 This study proposes an alternative tumor staging system for cutaneous squamous cell carcino

49 The proposed alternative tumor staging system offers improved prognostic discrimi

50 An alternative tumor staging system was developed with the aim of bette

51 ith log-rank testing for evaluation of the 2 tumor staging systems.

52 algorithms rendered an 89%-correct rate for tumor staging using genes differentially expressed betwe

53 Tumor staging was similar between groups.

54 liary body and choroidal) melanoma, the AJCC tumor staging was stage I in 2767 (36%), stage II in 373

55 patients who underwent (18)F-FDG PET/CT for tumor staging were identified from a database search.

56 Metastasis after initial tumor staging with 5- and 10-year Kaplan-Meier metastasi

57 red for hepatic resection after conventional tumor staging with computed tomography.

58 Laparoscopic US allows tumor staging without formal celiotomy, and many hepatic